A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

ClinicalTrials.gov ID: NCT07221500

Public ClinicalTrials.gov record NCT07221500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.

Study identification

NCT ID: NCT07221500
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Enrollment: 100 participants

Conditions and interventions

Conditions

Interventions

NX-5948 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 14, 2025
Primary completion: Dec 31, 2027
Completion: Sep 30, 2030
Last update posted: Aug 18, 2026

2025 – 2030

United States locations

U.S. sites: 25
U.S. states: 15
U.S. cities: 24

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Cedars-Sinai Medical Center	Los Angeles	California	90048	Recruiting
Scripps Health	San Diego	California	92121	Recruiting
Colorado Blood Institute	Denver	Colorado	80218	Recruiting
University of Miami	Coral Gables	Florida	33146	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
Fort Wayne Oncology and Hematology	Fort Wayne	Indiana	46804	Recruiting
Hematology Oncology of Indiana	Indianapolis	Indiana	46260	Recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
Maryland Oncology Hematology	Silver Spring	Maryland	20904	Recruiting
Karmanos Cancer Center	Detroit	Michigan	48201	Recruiting
Duke University	Durham	North Carolina	27705	Recruiting
Novant Health Cancer Institute	Winston-Salem	North Carolina	27103	Recruiting
University of Cincinnati	Cincinnati	Ohio	45221	Recruiting
The Cleveland Clinic Foundation	Cleveland	Ohio	44195	Recruiting
The Ohio State University	Columbus	Ohio	43210	Recruiting
Oncology Hematology Care	Fairfield	Ohio	45014	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
Texas Oncology - Center South	Austin	Texas	78705	Recruiting
University of Utah	Salt Lake City	Utah	84112	Recruiting
Virginia Cancer Specialists, PC	Fairfax	Virginia	22031	Recruiting
Oncology & Hematology Associates of Southwest VA	Norfolk	Virginia	23502	Recruiting
Virginia Oncology Associates	Norfolk	Virginia	23502	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07221500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2026 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07221500 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →